Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 6/20 | 0.87 |
| ▸ | DRD2 | P14416 | 2/20 | 0.68 |
| ▸ | DRD3 | P35462 | 2/20 | 0.68 |
| ▸ | DRD5 | P21918 | 1/20 | 0.68 |
| ▸ | HTR1A | P08908 | 2/20 | 0.64 |
| ▸ | DRD1 | P21728 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | HTR6 | P50406 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7663753 | 0.99 | HTR7 (0.85) | HTR7DRD2DRD3DRD5HTR1A | |
| SCHEMBL7668123 | 0.95 | HTR7 (0.95) | HTR7DRD2DRD3DRD5HTR1A | |
| Hydrochloric Acid SCHEMBL6866824 | 0.94 | HTR7 (0.93) | HTR7DRD2DRD3DRD5HTR1A | |
| SCHEMBL11465528 | 0.88 | SIGMAR1 (0.76) | HTR7DRD2DRD3HTR1ADRD1 | |
| SCHEMBL10836050 | 0.86 | HTR7 (0.72) | HTR7DRD2DRD3DRD5HTR1A | |
| SCHEMBL11167038 | 0.85 | HTR7 (0.68) | HTR7DRD2DRD3DRD5HTR1A | |
| SCHEMBL9364308 | 0.84 | SIGMAR1 (0.77) | HTR7DRD2DRD3DRD5 | |
| SCHEMBL5178743 | 0.84 | HTR7 (0.72) | HTR7DRD2DRD3DRD5HTR1A | |
| SCHEMBL9844900 | 0.83 | HTR1A (0.88) | HTR7DRD2DRD3DRD5HTR1A | |
| SCHEMBL21802017 | 0.83 | HTR7 (0.76) | HTR7DRD2DRD3DRD5HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812344-B1 | SYTHESIS OF COMPOUNDS FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | RANBAXY LABORATORIES LIMITED (IN) | 2004-11-02 | — | — | US | disclosed |
| US-6420559-B1 | THE COMPOUNDS ARE USEFUL FOR TREATMENT OF DISEASE CONDITIONS, SUCH AS PERIPHERAL VASCULAR DISEASE, CONGESTIVE HEART FAILURE, HYPERTENSION AND ESPECIALLY BENIGN PROSTATIC HYPERTROPHY. | RANBAXY LABORATORIES LIMITED (IN) | 2002-07-16 | — | — | US | disclosed |
| US-6420366-B1 | PERIPHERAL VASCULAR DISEASE, CONGESTIVE HEART FAILURE, HYPERTENSION AND ESPECIALLY BENIGN PROSTATIC HYPERTROPHY. | RANBAXY LABORATORIES LIMITED (IN) | 2002-07-16 | — | — | US | disclosed |
| US-6410735-B1 | CONGESTIVE HEART FAILURE; HYPOTENSIVE AGENTS; BENGIN PROSTATIC HYPERPLASIA | RANBAXY LABORATORIES LIMITED (IN) | 2002-06-25 | — | — | US | disclosed |
| US-6090809-A | 1-(4-arylpiperazin-1-yl)-ω-[n-(α..omega.-dicarboximido)]-alkanes useful as uro-selective α1 -adrenoceptor blockers | RANBAXY LABORATORIES LIMITED (IN) | 2000-07-18 | — | — | US | disclosed |
| US-6083950-A | TREATMENT OF PERIPHERAL VASCULAR DISEASE, CONGESTIVE HEART FAILURE, HYPERTENSION AND ESPECIALLY BENIGN PROSTATIC HYPERTROPHY | RANBAXY LABORATORIES LIMITED (IN) | 2000-07-04 | — | — | US | disclosed |